JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Aktien・Aclaris Therapeutics Inc

Search

Aclaris Therapeutics Inc

Geschlossen

4.41 1.85

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

4.33

Max

4.41

Schlüsselkennzahlen
By Trading Economics
Einkommen	-5.2M -20M
Verkäufe	-2M 1.3M
Gewinnspanne	-1,528.571
Angestellte	69
EBITDA	-5.3M -20M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+156.92% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	7. Mai 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	264M 616M
Vorheriger Eröffnungskurs	2.56
Vorheriger Schlusskurs	4.41

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

1.28 / 1.33 Unterstützung & Widerstand

Aclaris Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Mai 2026, 22:17 UTC

Ergebnisse

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4. Mai 2026, 23:47 UTC

Ergebnisse

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4. Mai 2026, 23:45 UTC

Ergebnisse

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4. Mai 2026, 23:45 UTC

Ergebnisse

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4. Mai 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

4. Mai 2026, 22:44 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Jim Beyer To Be Chief Executive of Combined Company

4. Mai 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4. Mai 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4. Mai 2026, 22:42 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4. Mai 2026, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4. Mai 2026, 22:41 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Shareholders to Own About 51% of Combined Company

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Board Unanimously Endorsed, Supported Deal

4. Mai 2026, 22:40 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Deal Unanimously Recommended by Vault Board

4. Mai 2026, 22:39 UTC

Akquisitionen, Fusionen, Übernahmen

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4. Mai 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Regis Resources to Acquire All Ordinary Shares in Vault

4. Mai 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Regis Resources, Vault Minerals Agree to Merger of Equals

4. Mai 2026, 22:37 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4. Mai 2026, 22:26 UTC

Ergebnisse

Akquisitionen, Fusionen, Übernahmen

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4. Mai 2026, 22:02 UTC

Ergebnisse

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4. Mai 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4. Mai 2026, 21:52 UTC

Ergebnisse

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4. Mai 2026, 21:50 UTC

Ergebnisse

Westpac: Some Sectors More Affected Than Others>WBC.AU

4. Mai 2026, 21:50 UTC

Ergebnisse

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4. Mai 2026, 21:49 UTC

Ergebnisse

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4. Mai 2026, 21:44 UTC

Ergebnisse

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4. Mai 2026, 21:44 UTC

Ergebnisse

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4. Mai 2026, 21:43 UTC

Ergebnisse

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4. Mai 2026, 21:41 UTC

Ergebnisse

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4. Mai 2026, 21:40 UTC

Ergebnisse

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer-Vergleich

Kursveränderung

Aclaris Therapeutics Inc Prognose

Kursziel

By TipRanks

156.92% Vorteil

12-Monats-Prognose

Durchschnitt 11.33 USD 156.92%

Hoch 16 USD

Tief 10 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Aclaris Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Basierend auf 6 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Aclaris Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.28 / 1.33Unterstützung & Widerstand

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Andere Aktien aus dem Sektor

JNJ

Johnson and Johnson

225.57

UNH

UnitedHealth Group Inc

363.82

TMO

Thermo Fisher Scientific Inc

466.62

ISRG

Intuitive Surgical Inc

451.55

ABT

Abbott Laboratories

87.15

Live chat